:max_bytes(150000):strip_icc()/GettyImages-2217857103-0b3f8490b6bc4480a177ce5d257230e0.jpg "This Drugmaker’s Stock Is Soaring Over 40% Monday")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2217857103-0b3f8490b6bc4480a177ce5d257230e0.jpg)
Key Takeaways
- Kymera Therapeutics reported positive results from a trial of its experimental anti-inflammatory drug, sending shares higher Monday.
- The company said the results exceeded expectations for patients with eczema and asthma.
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
The company said a Phase 1b trial of its KT-621 drug found it can help significantly reduce inflammation for patients with eczema and asthma. The treatment works by targeting STAT6, a protein that affects immune responses.
CEO Nello Mainolfi said the results “exceeded our highest expectations and provide a powerful additional validation of our industry-leading STAT6 degrader program.”
Why This Is Significant
Drug stocks can get a big boost from promising new treatments and trials, with Monday’s big stock gains for Kymera Therapeutics pointing to optimism about its KT-621.
Kymera said that a Phase 2b trial of KT-621 for those with eczema is already underway, and it expects results by mid-2027. A second Phase 2b trial for asthma patients is scheduled to start in the first quarter of next year.
With Monday’s gains, Kymera Therapeutics shares are up about 140% year-to-date.
